Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug development in prostate cancer.

G H Ripple1, G Wilding

  • 1Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, USA.

Seminars in Oncology
|December 22, 1999
PubMed
Summary

New prostate cancer therapies targeting tumor biology show promise but require novel clinical trial designs. Improving patient enrollment in trials is crucial for assessing these innovative treatments and enhancing outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Timing of the definitive procedure and ileostomy closure for total colonic aganglionosis HD: Systematic review.

Journal of pediatric surgery·2020
Same author

Small bowel fed response as measured by wireless motility capsule: Comparative analysis in healthy, gastroparetic, and constipated subjects.

Neurogastroenterology and motility·2017
Same author

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.

British journal of cancer·2016
Same author

Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Variable abnormal physiological motility in the proximal upper gastrointestinal tract in gastroparesis.

Neurogastroenterology and motility·2012

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trials

Background:

  • Prostate cancer is a significant cause of male morbidity and mortality.
  • Metastatic hormone-refractory prostate cancer (HRPC) has limited treatment options.
  • Advances in understanding tumor biology reveal new therapeutic targets.

Purpose of the Study:

  • To highlight challenges in evaluating novel prostate cancer therapies.
  • To emphasize the need for innovative clinical trial designs.
  • To advocate for increased patient participation in clinical trials.

Main Methods:

  • Discussion of emerging therapeutic targets (apoptosis, angiogenesis, etc.).
  • Examples of agents in clinical trials (perillyl alcohol, vitamin D analogs, flavopiridol, angiogenesis inhibitors).
  • Analysis of limitations in current study designs and efficacy parameters.

Main Results:

  • Novel agents target specific cellular pathways, requiring new evaluation methods.
  • Current trial designs may not adequately assess the efficacy of these targeted therapies.
  • Low patient enrollment in clinical trials hinders progress.

Conclusions:

  • Novel approaches are needed to determine the clinical utility of new prostate cancer therapies.
  • Enhanced clinical trial designs and increased patient enrollment are essential.
  • Improving the assessment of promising treatments can lead to better patient outcomes.

Related Experiment Videos